Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 2/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089708 | 0.86 | FOLH1 (0.61) | FOLH1RIMKLANAALAD2CCKBR | |
| SCHEMBL18538622 | 0.80 | FPR2 (0.47) | FPR2FOLH1RIMKLANAALAD2SMN1; SMN2 | |
| SCHEMBL18538620 | 0.79 | FOLH1 (0.48) | FPR2FOLH1SMN1; SMN2 | |
| SCHEMBL18253627 | 0.77 | FOLH1 (0.49) | FPR2FOLH1RIMKLANAALAD2SMN1; SMN2 | |
| SCHEMBL19788064 | 0.77 | FOLH1 (0.49) | FPR2FOLH1RIMKLANAALAD2SMN1; SMN2 | |
| SCHEMBL10089711 | 0.73 | FOLH1 (0.67) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL13559294 | 0.73 | FOLH1 (0.67) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19703744 | 0.73 | EPHX1 (0.53) | SMN1; SMN2KDM4CCCKBR | |
| SCHEMBL26830774 | 0.73 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL23874511 | 0.73 | EPHX1 (0.54) | SMN1; SMN2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556167-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | FPR2 410/4885FOLH1 12/4885RIMKLA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.